Figure 1
From: Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis
Anti-IL-6 decreased incidence of CIA. DBA/1 LacJ mice were dosed IP with anti-IL-6 antibody (1 mg or 5 mg/mouse) or irrelevant control antibody (1 mg/mouse) two days prior to injection with collagen and weekly IP for 10 weeks (n = 10 mice/group). Percent disease represents the percentage of mice/group with clinical signs of arthritis (having at least one diseased paw). Statistical differences between the groups were determined using the Kruskal-Wallis test for multiple samples (SPSS Inc, Chicago, IL).